Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

A Phase 1 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors.

The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity.

The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.

Study Overview

• Status: Recruiting
• Conditions: Stage IV Melanoma; Stage III Melanoma
• Intervention / Treatment: Biological: TBX-3400

• Study Type: Interventional
• Enrollment (Anticipated): 72
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Yosef Refaeli, PhD; Phone Number: +1-720-859-3547; Email: refaeli@taigabiotech.com
• Study Contact Backup: Name: Vivienne Margolis; Phone Number: +972-52-463-9634; Email: vmargolis@taigabiotech.com

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90025
      • Recruiting
      • The Angeles Clinic and Research Institute
      • Contact: Dr. Inderjit Mehmi, MD; Phone Number: 310-294-0438; Email: imehmi@theangelesclinic.org
  • Colorado
    • Denver, Colorado, United States, 80045
      • Recruiting
      • University of Colorado Cancer Center
      • Contact: Theresa Medina, MD; Phone Number: 720-848-7135; Email: Theresa.Medina@ucdenver.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for participation in the study:

1. Histopathologically confirmed diagnosis of advanced, unresectable or metastatic malignant melanoma
2. Male or female patients age 18 or older
3. Previously treated with checkpoint inhibitor therapy either alone or in combination with either stable disease or progressive disease per RECIST version 1.1 (there is no minimum treatment duration for patients who have progressive disease while on checkpoint inhibitor therapy)
4. Measurable or evaluable disease by RECIST version 1.1
5. Capable of understanding and complying with protocol requirements
6. A life expectancy of greater than 24 weeks at Screening
7. ECOG Performance Status of 0 to 2
8. Written informed consent from the patient or the patient's legally acceptable representative prior to the initiation of any study procedures

9. Adequate bone marrow, liver, and renal function as defined below:

   • hemoglobin ≥8.0 g/dL (transfusions allowed)
   • absolute neutrophil count ≥1500/µL
   • platelet count ≥100,000/µL (transfusions allowed)
   • alanine transaminase and aspartate transaminase ≤3.0 times the upper limit of normal (ULN), or ≤5 times ULN for patients with known hepatic metastases
   • total serum bilirubin ≤1.5 x the ULN; ≤2.0 x the ULN if liver metastases are present; patients with a known history of Gilbert's syndrome (≤3.0 x the ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation
   • estimated glomerular filtration rate ≥50 mL/min/1.73 m^2 (using Cockcroft Gault formula)

Exclusion Criteria:

Patients who meet any of the following criteria will not be eligible for participation in the study:

1. Pregnant or breast feeding
2. Developed immune-related toxicity while on prior checkpoint inhibitor therapy that has not yet returned to Grade 1 or better
3. Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted
4. Active, symptomatic central nervous system (CNS) metastases. Patients with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy and the patient is off corticosteroids and is neurologically stable for at least 7 days prior to screening
5. Any concurrent uncontrolled illness, including mental illness or substance abuse which in the opinion of the investigator would make the patient unable to cooperate or participate in the trial
6. Severe uncontrolled cardiac disease within 3 months of study entry, including unstable or new onset angina, myocardial infarction or cerebrovascular accident
7. Women of childbearing potential who are unable or unwilling to use an acceptable method of contraception
8. Known infection with human immunodeficiency virus (HIV) that is not well controlled on anti-retroviral therapy as defined by HIV RNA more than 400 copies/mL or severely symptomatic
9. Presence of Hepatitis B and/or Hepatitis C active infection
10. Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TBX-3400; TBX-3400 by intravenous infusion	Biological: TBX-3400; Autologous transfusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03	Adverse events from subject reporting	26 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor responses as defined by RECIST version 1.1	Tumor measurements to assess disease state	26 months
Tumor responses as defined by irRECIST	Tumor measurements to assess disease state	26 months
Assessment of concentrations of certain chemokines, such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400	Preliminary efficacy assessment to measure activity of TBX-3400	26 months
Presence and/or concentration of anti TBX-3400 antibodies	Measure of immunogenicity of TBX-3400	26 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quantification of the concentration of interleukin-1 (IL-1) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	26 months
Quantification of the concentration of interleukin-6 (IL-6) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	26 months
Quantification of the concentration of interferon-alpha (INF-α) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	26 months
Quantification of the concentration of interferon gamma inducible protein 10 kD (IP-10) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	26 months
Quantification of the concentration of interferon-gamma (IFN-γ) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	26 months
Quantification of the concentration of transforming growth factor-beta (TGF-ß) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	26 months

Collaborators and Investigators

• Sponsor: Taiga Biotechnologies, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): June 2, 2019
• Primary Completion (Anticipated): February 1, 2023
• Study Completion (Anticipated): December 1, 2024

Study Registration Dates

• First Submitted: December 3, 2017
• First Submitted That Met QC Criteria: December 20, 2017
• First Posted (Actual): December 28, 2017

Study Record Updates

• Last Update Posted (Actual): May 3, 2022
• Last Update Submitted That Met QC Criteria: May 1, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Refractory; Melanoma; Resistant
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma
• Other Study ID Numbers: TBX-3400-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No